Skip to main content
MIB Agents OsteoBites

MIB Agents OsteoBites

By Ann Graham

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
Available on
Apple Podcasts Logo
Google Podcasts Logo
Overcast Logo
Pocket Casts Logo
RadioPublic Logo
Spotify Logo
Currently playing episode

The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals

MIB Agents OsteoBites May 06, 2022

00:00
58:50
osTEAo: Patient Experiences with Lung Surgery for Osteosarcoma

osTEAo: Patient Experiences with Lung Surgery for Osteosarcoma

Camille and Mia are joined by OsteoWarriors Jasmine, Penelope and Walker to share their experiences with local control strategies to remove osteosarcoma lung metastasis, including surgery, radiation therapy, and cryoablation. They cover everything from their reaction to hearing they needed a lung surgery, how they prepared for surgery - both mentally and pro tips for how to make yourself comfortable in the hospital, managing their pain and nausea post surgery, recovery time for the different types of procedures, and their individual outcomes post procedure. In addition to hearing about their personal experiences, you'll learn about the power of escapism TV, why a spirometer can be scary, the wonders of a Da Vinci robot, and the technical term for stabby-stabby, freezy-freezy

Mar 21, 202401:16:13
Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research

Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research

Donghan “Mo” Yang, PhD, is a researcher in the field of data science and health informatics.  He joins us on OsteoBites to introduce the development of the Osteosarcoma Explorer (OSE), a data commons with clinical, genomic, protein, and tissue imaging data for osteosarcoma research. The OSE is one of the flagship projects cultivated within the CPRIT-funded Pediatric Cancer Data Core (Director: Yang Xie, PhD, Professor and Associate Dean of Data Science, UT Southwestern). The goal of the OSE project is to integrate publicly available and institutional osteosarcoma data of various types and share them with the research community via an interactive web interface. The OSE web portal is now accessible to the public at https://datacommons.swmed.edu/cce/ose.Dr. Yang is an Assistant Professor and a Texas Health Resources Clinical Scholar in the Quantitative Biomedical Research Center at Peter O’Donnell Jr. School of Public Health, UT Southwestern Medical Center. He also serves as the Director of Biostatistics and Data Science Core at UT Southwestern. Dr. Yang’s research focuses on developing methods, platforms, and infrastructure for the management, integration, and analysis of real-world healthcare data, including electronic health records, imaging, and molecular profiling data. He has led team efforts of building data commons – comprehensive database interfaced by user-friendly web portal – for adult and childhood cancers and other diseases. He also applies advanced analytics to gain insights from these real-world data resources.

Mar 14, 202401:04:45
Patient perspectives on participating in research and clinical trials

Patient perspectives on participating in research and clinical trials

Jennifer Mack, MD, MPH from Dana-Farber Cancer Institute/Boston Children’s and Harvard Medical School join us on OsteoBites to discuss best practices for engaging patients in research and clinical trials. Dr. Mack is also part of the PE-CGS Network (Participant Engagement and Cancer Genome Sequencing) Count Me In Research Center team and she will be discussing reasons that patients may or may not want to participate in research, ways to engage patients in designing and carrying out trials., and Count Me In as one model for engaging patients.Dr. Mack received her medical degree from Harvard Medical School in 1998. She subsequently completed her residency in Pediatrics and her fellowship in Pediatric Hematology Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute in Boston, MA. In 2005, Dr. Mack received a Master’s Degree in Public Health from the Harvard School of Public Health. She is an attending physician at Dana-Farber Cancer Institute and Boston Children's Hospital, Director of the Center for Outcomes and Policy Research at Dana-Farber, Associate Chief of the Division of Population Sciences at Dana-Farber, Associate Chief for Pediatric Oncology Population Sciences at Dana-Farber/Boston Children’s, and Faculty Vice President for the Office for Faculty Development, Professionalism, and Inclusion at Dana-Farber. She is also an Associate Professor of Pediatrics at Harvard Medical School. Her research interests are in parent-clinician and patient-clinician communication, health care equity and quality, and palliative care.

Mar 08, 202401:02:56
Tissue Engineering Strategies for Elucidating Osteosarcoma Biology and Drug Discovery

Tissue Engineering Strategies for Elucidating Osteosarcoma Biology and Drug Discovery

Fan Yang, PhD is an Associate Professor at Stanford University with joint appointments in the Departments of Orthopaedic Surgery and Bioengineering joins OsteoBites to discuss her work on tissue engineering strategies for elucidating OS biology and drug discovery.Fan Yang, PhD is the founder and Director of Stanford Stem Cells and Biomaterials Engineering Laboratory, and also Co-director of Stanford NIH Biotechnology Training Program. Her research seeks to develop hydrogels with unique micro- and nano- scale properties to promote stem cell differentiation, tissue regeneration and immunomodulation, with a focus on musculoskeletal diseases. Her lab also harnesses biomaterials to create 3D cancer models with in vivo-mimicking phenotype and drug responses. Such 3D models could enable discovering novel druggable targets that would otherwise be missed using conventional 2D culture, and enable high-throughput drug screening with reduced cost and time than animal models. Prior to joining Stanford, Dr. Yang received her Ph.D. in Biomedical Engineering from Johns Hopkins University, and then completed a postdoctoral fellowship at MIT under Prof. Robert Langer. In recognition of her innovation, she has been recognized by numerous awards including Fellow of American Institute for Medical and Biological Engineering, MIT TR35 Global list honoree, National Science Foundation CAREER award, Young Investigator Award from Society for Biomaterials, Biomaterials Science Lectureship Award, Young Investigator award from Alliance for Cancer and Gene Therapy, Ellen Weaver Award by the Association for Women in Science, Baxter Faculty Scholar Award, the McCormick Faculty Award, Stanford Asian American Faculty Award, and the Basil O’Connor Starter Scholar Research Award, etc.

Mar 01, 202401:04:21
Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study

Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study

Dr. David Shulman is a pediatric oncologist at Dana-Farber Cancer Institute. He studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas. He joins us on OsteoBites to discuss the LEOPARD Study: Liquid Biopsy in Ewing sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic

Feb 23, 202401:01:04
Managing Stress in AYA Cancer Patients

Managing Stress in AYA Cancer Patients

A cancer diagnosis and the treatment that follows can trigger stress and anxiety. Camille is joined this week by Dr. Abby Rosenberg, an expert in helping AYA cancer patients manage stress. They chat about why being diagnosed as an adolescent/young adult has particular challenges, tools and techniques for managing stress, and how palliative care is different from hospice care (spoiler alert - it's not just for end of life care!). Listen in to learn why stress is normal, the three categories of resilience resources, the power of distraction, the benefit of emotions, and how palliative care helps the entire care team focus on what is important to the patient. Abby R. Rosenberg, MD, MS, MA, joined the team at Boston Children's Hospital as the Director of Palliative Care in 2023. She is also the Chief of Pediatric Palliative Care at the Dana-Farber Cancer Institute. Prior to that, she was at the University of Washington and Seattle Children’s Hospital, where she served as the Director of Survivorship and Outcomes Research and Director of Pediatrics at the Cambia Palliative Care Center of Excellence. Both Dr. Rosenberg’s clinical approach and her research focus on helping people facing serious illness to live their best lives, for as long as possible. Specifically, she and her team develop programs that help patients and families build resilience and optimize their quality of life.

Feb 15, 202437:50
Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma

Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma

David Freyer, DO, MS provides a review of hearing loss as a serious and permanent side effect caused by cisplatin chemotherapy, recent research regarding its prevention, and its relevance for young people treated for osteosarcoma.David R. Freyer, DO, MS is Professor of Clinical Pediatrics, Medicine, and Population and Public Health Sciences at the Keck School of Medicine, University of Southern California. He currently serves as Director of the Survivorship and Supportive Care Program in the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles, and as Director of the Cancer Survivorship Program and Co-Director of the Adolescent and Young Adult Cancer Program, both at the USC Norris Comprehensive Cancer Center. Dr. Freyer’s clinical care and research are concentrated in cancer survivorship, cancer control/supportive care, and AYA oncology with interests in treatment-related toxicity, survivorship care transition, cancer care disparities, and patient-reported outcomes. He had the privilege of leading ACCL0431, a randomized Children's Oncology Group study and pivotal trial leading to FDA approval of sodium thiosulfate as the first proven agent to prevent cisplatin-induced hearing loss in young people treated for cancer.

Feb 09, 202401:00:31
TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma

TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma

Dr. Andy Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology, and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas. Dr. Livingston joins us on OsteoBites to discuss the background and scientific rationale for combining immunotherapy with cabozantinib in teens and young adults with osteosarcoma and provide information about the ongoing TACOS study: Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma.Dr. Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology at MD Anderson Cancer Center in Houston, Texas. After completing medical school at the University of Texas Medical Branch at Galveston, he went on to residency training at Duke University where he completed a combined residency in internal medicine and pediatrics. Dr. Livingston completed his fellowship training at MD Anderson where he served as the Chief Fellow for Hematology/Oncology Fellowship Program. Dr. Livingston has a particular interest in the care of teens and young adults with cancer and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas. He received the MIB OutSmarting Osteosarcoma award in 2020 for his work on the immune landscape of osteosarcoma and serves as a member of the MIB Scientific Advisory Board.

Jan 26, 202459:54
osTEAo: Making friends after a cancer diagnosis

osTEAo: Making friends after a cancer diagnosis

Camille and Mia kick off Season 3 of osTEAo with a chat on friendships after a cancer diagnosis. With special guest Vicky, MIB Agents 2023 Junior Advisory Board president, Camille and Mia discuss how to rebuild a life with meaningful connections and friendships when treatment removes you from school, your sports and extracurricular activities, and seeing your friends everyday. In this frank and sometimes hilarious discussion, you'll hear about the shift from quality to quantity, the positive effects of "opposite action", the value of long distance relationships, and the beauty of mocktails and staying in.

Jan 18, 202447:35
Interventions to promote physical function during and after treatment for osteosarcoma

Interventions to promote physical function during and after treatment for osteosarcoma

Osteosarcoma Webinar Series: Keri Schadler, PhD and Kiri Ness, PT, PhD, FAPTA will partner to provide information about the importance of exercise for patients undergoing treatment as well as long term survivors of osteosarcoma. Together, they will provide a clinical perspective as well as an overview of the latest evidence that documents the need for and the initial success of exercise intervention during and after treatment for cancer.


Dr. Schadler is an Associate Professor in the Department of Pediatrics at MD Anderson Cancer Center. Her lab utilizes mouse models and collaborations with clinical investigators to delineate the multi-faceted effects of exercise on the tumor microenvironment. Specifically, the Schadler lab aims to understand how exercise changes cellular and molecular signaling within the tumor vasculature and immune cells, and to use exercise as a tool to enhance tumor response to standard therapies.


Dr. Ness is a physical therapist and clinical epidemiologist whose research focuses on the late effects of childhood and adolescent cancer and its treatment. She has a particular interest in human movement and performance, designing interventions to prevent functional loss during therapy or remediate impairment following curative treatment. She has over 350 peer reviewed original research papers and has had continuous funding to support her work since 2005. She is the MPI of the St. Jude Lifetime Cohort and PI of the Human Performance Laboratory at St. Jude Children's Research Hospital.

Jan 11, 202401:00:02
The Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan (CAUSAL) study

The Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan (CAUSAL) study

Debra L. Friedman, M.D., is a professor of Pediatrics in the Division of Hematology and Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. She is the E. Bronson Ingram Chair of Pediatric Oncology and the leader of the Cancer Control and Prevention Program and directs the Cancer Survivorship programs at the Vanderbilt-Ingram Cancer Center. Dr. Friedman's research interests lie in the long term outcomes for cancer survivors, as well as in the design of novel therapeutic protocols for childhood cancer, designed to decrease adverse long-term effects of therapy. She has leadership roles in Children's Oncology Group (COG) and is an internationally recognized expert in cancer survivorship, participating in projects evaluating best practices and models of care. She is investigating a diverse group of physiologic and psychosocial outcomes among survivors of pediatric cancer, hematopoietic stem cell transplant and medical oncology. Friedman completed her pediatric residency and a joint fellowship in Pediatric Hematology/Oncology and Cancer Epidemiology at the University of Pennsylvania and The Children's Hospital of Philadelphia (CHOP). Prior to coming to Vanderbilt in 2008, she served as the co-director of the Cancer Survivorship Program at CHOP and then, as the founder and director of the Fred Hutchinson Cancer Research Center Survivorship Program.

----

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Dec 15, 202336:44
Developing a Multiscale Transcriptional Atlas of Sarcoma
Dec 08, 202358:45
Immunological Mechanisms of Cancer Defense

Immunological Mechanisms of Cancer Defense

Ming Li, PhD, is Member of the Immunology Program at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Graduate School of Medical Sciences. His laboratory studies immune regulation and its relevance to diseases including cancer. Recent work has focused on the signaling, metabolic, and transcriptional mechanisms of T cell regulation as well as tumor-elicited innate and adaptive immune responses, and how this knowledge can be translated for novel cancer immunotherapy. Dr. Li received his PhD in Biological Sciences from Columbia University, and postdoctoral training at Yale University. Dr. Li is an American Academy of Arts and Sciences (AAAS) Fellow and has received a number of honors including a Howard Hughes Medical Institute (HHMI) Faculty Scholar Award, a Rita Allen Foundation Scholar Award, an American Cancer Society Scholar award, and the 2016 American Association of Immunologists (AAI)-BD Bioscience Investigator Award for outstanding contributions to the field of immunology.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Dec 01, 202359:04
osTEAo: Long Term Osteosarcoma Survivors: Where They Were and Where They Are Now
Nov 16, 202301:05:49
Cabozantinib as a Maintenance Therapy to Prevent Recurrence of High-Risk Pediatric Solid Tumors

Cabozantinib as a Maintenance Therapy to Prevent Recurrence of High-Risk Pediatric Solid Tumors

Nilay Shah, MD is a clinician-scientist and Associate Professor in the Division of Hematology/Oncology/BMT at Nationwide Children’s Hospital. His primary clinical focus is on pediatric solid tumors, including neuroblastomas, tumors of the kidneys, and rare solid tumors of childhood. His research focuses on the molecular drivers of pediatric cancers and how new treatment approaches can be taken to better target those drivers. In this role, he works to identify new uses of currently available anticancer treatments, including drugs originally developed for use against cancers in adults. He serves as Associate Director for Liver Tumor, Kidney Tumor, Germ Cell, and Neuroblastoma Targeted Therapies, and is currently the Sponsor and Study Principal Investigator the CaboMain trial, a Phase 2 study evaluating the efficacy of the oral anticancer agent cabozantinib as a maintenance therapy for ultra-high-risk solid tumors.


He also serves as co-director of the Cancer Genetics Program. This program serves to advance the use of genetic and genomic evaluations for the benefits of patients. In this role, he sees patients in the Cancer Predisposition Clinic for evaluation, surveillance, and management of patients with genetic alterations that predispose to cancer development. He also consults on patients for precision oncology, partnering with the Institute for Genomic Medicine to identify therapeutic approaches based on patient tumor and germline genomics.


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Oct 27, 202301:03:27
osTEAo - Coping with Cancer through Music

osTEAo - Coping with Cancer through Music

In this episode, OsteoWarriors Camille and Mia share songs that have resonated with them during their life with cancer. Find out why Fight Song is not their preferred anthem for AYA cancer patients and why hope can feel like a four letter word. Listen in as they break down lyrics, discuss why osteosarcoma is like a masochistic toxic ex, and examine how music can heal and help validate the feelings and emotions that AYA cancer patients deal with. You can also listen to these meaningful musical selections on a special Spotify playlist by copying and pasting the link here into your web browser, or scanning the QR code :

https://open.spotify.com/playlist/6ARr8egX2vQ23Aql1ypSb5?si=0d1d2abf6da44cb5


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Oct 19, 202359:44
OsteoBites Preguntas & Respuestas con Nino Rainusso, MD

OsteoBites Preguntas & Respuestas con Nino Rainusso, MD

OsteoBites Preguntas & Respuestas con Nino Rainusso, MD: Únase a nosotros para un episodio especial de OsteoBites en español. Nino Rainusso, MD del Texas Children's Hospital con preguntas de respuesta sobre el osteosarcoma de pacientes y cuidadores.


El Dr. Nino Rainusso es miembro del equipo de tumores sólidos pediátricos y codirector del programa de cardiooncología del Texas Children's Hospital - Baylor College of Medicine. Su laboratorio se centra en comprender el papel de las células madre cancerosas (CSC) tanto en el desarrollo de tumores como en la resistencia a la quimioterapia en sarcomas pediátricos. Ha realizado varios estudios destinados a caracterizar las CSC en tumores óseos pediátricos. Han desarrollado varios modelos de xenoinjerto derivado de paciente (PDX) de osteosarcoma, sarcoma de Ewing, rabdomiosarcoma y sarcomas de tejidos blandos. Su laboratorio participa actualmente en un proyecto PDX multiinstitucional destinado a caracterizar y evaluar el impacto de nuevos enfoques terapéuticos en cánceres pediátricos que utilizan PDX.


Dr. Nino Rainusso is a member of the Pediatric Solid Tumor Team and Co-Director of the Cardio-Oncology Program at Texas Children’s Hospital - Baylor College of Medicine. Their laboratory focuses on understanding the role of cancer stem cells (CSCs) in both tumor development and chemotherapy resistance in pediatric sarcomas. He has conducted several studies aimed to characterize CSCs in pediatric bone tumors. They have developed several patient-derived xenograft (PDX) models of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and soft-tissue sarcomas. Their laboratory currently participates in a multi-institutional PDX project aimed to characterize and to evaluate the impact of novel therapeutic approaches in pediatric cancers using PDXs.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Oct 13, 202355:39
TCF-001 TRACK (Target Rare Cancer Knowledge): A Clinical Trial Studying Precision Medicine in Rare Cancers

TCF-001 TRACK (Target Rare Cancer Knowledge): A Clinical Trial Studying Precision Medicine in Rare Cancers

TCF-001 TRACK is a patient advocacy initiated, decentralized clinical trial enrolling patients with rare cancers and cancer of unknown primary. Patients can enroll remotely without a requirement to travel, and enrolled patients receive biomarker testing of tissue and blood at no cost, as well as treatment recommendations from a virtual molecular tumor board. This presentation will provide details on how TRACK works, and how it seeks to achieve its goals of providing patients with personalized, potentially actionable information while simultaneously generating critical research data.


Jim Palma is the Executive Director of TargetCancer Foundation. Since joining TargetCancer Foundation in 2010, Jim has overseen its growth from a small start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services. Prior to joining TargetCancer Foundation, he spent eleven years at Fidelity Investments in Boston, MA. Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD), and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim is a Steering Committee member at the GI Cancers Alliance and the Global Cholangiocarcinoma Alliance. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland.


---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Oct 06, 202359:56
Repurposing Disulfiram to Overcome Chemotherapy Resistance in Relapsed Sarcomas

Repurposing Disulfiram to Overcome Chemotherapy Resistance in Relapsed Sarcomas

Matteo Trucco, MD and Kurt Weiss, MD joins us on OsteoBites to describe the collaboration that led to the current Phase 1 clinical trial repurposing the alcoholism drug disulfiram to see if it can overcome the chemotherapy resistance seen in relapsed sarcomas, including osteosarcoma.


Matteo Trucco is a Pediatric Oncologist and the Clinical Director of Pediatric Hematology/Oncology at Cleveland Clinic Children’s, specializing in the care of children, teenagers and young adults battling bone and soft tissue cancers. He also directs the Children’s Cancer Innovative Therapy Program where he and colleagues design, develop and conduct clinical trials seeking more effective and less toxic treatments for childhood cancers. Dr. Trucco earned his undergraduate degree from the University of Pennsylvania and Medical Degree from Temple University School of Medicine. He completed his Pediatrics Residency at Rainbow Babies and Children’s Hospital and his Pediatric Hematology/Oncology Fellowship from Johns Hopkins and the National Cancer Institute. In addition to his roles at the Cleveland Clinic, he is a Co-chair of the National Pediatric Cancer Foundation’s Sunshine Project consortium, partnering with other top pediatric cancer centers to develop clinical trials. He is honored to be on the Board of MIB Agents, chairs its Scientific Advisory Board and co-chairs the organizing committee for the FACTOR Conference. He also has the privilege of moderating the MIB Agents TURBO Tumor Review Board for Osteosarcoma.


Dr. Weiss directs the Department’s Musculoskeletal Oncology Laboratory, a basic science laboratory dedicated to the study of sarcomas. His mission is to help develop a world-class translational sarcoma research program at the University of Pittsburgh. As a bone cancer survivor himself, Dr. Weiss brings passion and enthusiasm to the laboratory, clinic, and operating room. Through the UPMC Hillman Cancer Center, he is also a proud collaborator with scientists who are trying to understand how other forms of cancer spread to and destroy the bone. Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and others. He is a former member of the NIH’s Center for Scientific Review Early Career Reviewer program. He has served on multiple National Cancer Institute Study Sections. He is a member of the Musculoskeletal Tumor Society (MSTS) for which he serves as Chair of the Research Committee and the Connective Tissue Oncology Society (CTOS), for which he has served on the Board of Directors.

-----

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Sep 29, 202359:51
osTEAo Tea Spill: AYA Cancer Gab Sesh
Sep 20, 202358:04
Addressing the Unmet Scientific Challenges in Osteosarcoma Treatment through Innovative Engineering Techniques

Addressing the Unmet Scientific Challenges in Osteosarcoma Treatment through Innovative Engineering Techniques

Dr. Fiona Freeman is an Assistant Professor in the School of Mechanical and Materials Engineering at University College Dublin (UCD). She graduated in Biomedical Engineering in 2011 and earned her PhD from the University of Galway in 2016, focusing on developing new strategies for bone tissue regeneration. Afterward, Dr. Freeman was awarded two prestigious postdoctoral fellowships: the Government of Ireland IRC Postdoctoral Research Fellowship and the Marie Skłodowska-Curie Global Fellowship. These fellowships provided her with opportunities to work as a postdoctoral researcher in renowned labs at Massachusetts Institute of Technology (MIT), Brigham and Women's Hospital, Johns Hopkins University, and Trinity College Dublin.

In September 2022, Dr. Freeman was appointed as the first Ad Astra fellow in the School of Mechanical and Materials Engineering. Her current research focuses on using innovative engineering techniques to gain a better understanding of and develop novel therapeutics for treating osteosarcoma, a paediatric bone cancer. As part of her research, Dr. Freeman identified a novel microRNA, miR-29b, as a potential therapeutic target for osteosarcoma. She formulated miR-29b nanoparticles and delivered the miRNA to the tumour site using a hyaluronic-based hydrogel delivery system. The results showed a significant decrease in tumour burden, increased survival rates, and enhanced regeneration of the damaged bone surrounding the tumour.

These findings have the potential to revolutionize osteosarcoma treatment and improve patient outcomes by significantly reducing the primary tumour mass and providing crucial data that will inform the design of future therapies for young patients. Dr. Freeman conducted this work in collaboration with researchers at MIT and Brigham and Women's Hospital. In the coming years, Dr. Freeman is dedicated to building upon this research and advancing this technology toward clinical application.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Sep 15, 202358:04
Implementing Multi-Targeted Tyrosine Kinase Inhibitors in Combination with Chemotherapy for Osteosarcoma

Implementing Multi-Targeted Tyrosine Kinase Inhibitors in Combination with Chemotherapy for Osteosarcoma

This episode is sponsored is by BTG Pharmaceuticals


Dr. Michael Bishop is an Assistant Member in the Solid Tumor Division of the Department of Oncology at St. Jude Children’s Hospital in Memphis, TN. His clinical practice focuses primarily on the management of children and young adults with bone and soft tissue sarcomas, and his research interests are dedicated to the development of prospective clinical trials for the treatment of osteosarcoma. Dr. Bishop graduated from the University of Arkansas College of Medicine and completed his pediatric residency at Children’s Mercy Kansas City, and fellowship in pediatric hematology and oncology at Cincinnati Children’s Hospital Medical Center. Dr. Bishop is a member of the Children’s Oncology Group Bone Tumor Committee and is the Study Chair for AOST2032, a prospective trial assessing the feasibility and efficacy of combining a multi-targeted tyrosine kinase inhibitor with chemotherapy for newly diagnosed osteosarcoma.


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Sep 01, 202301:03:01
Immune Therapies in EGFR-Expressing Cancers

Immune Therapies in EGFR-Expressing Cancers

This presentation discusses key findings in immunotherapies from the investigator's laboratory as well as those that have shaped the landscape of both human and canine cancers. The information focuses on EGFR and HER2 based immunotherapies, including osteosarcoma, hemangiosarcoma and other cancer types in canine patients. Mechanisms of tumor growth and therapy will also be topics of discussions.

---

UCLA (B.A.), Univ Notre Dame (M.S.), University of Oklahoma Health Sciences Center (Ph.D.), Yale University School of Medicine (Professor of Medicine). Dr. Mamula’s interests are in investigating the early events of inflammatory mediated changes in the proteome that intersect with cellular metabolism and with breaking immune tolerance to self proteins. These studies have been applied to the development of novel immune-therapeutic approaches in for antitumor vaccines in EGFR/HER2 expressing cancers, including breast cancer and colon cancer. In particular, the work has evolved to clinical trials in companion canine populations. Overall, it is the goal of Dr. Mamula’s laboratory to understand the mechanisms that may shift the balance of the cellular proteome toward the initiation of anti-self immune responses. In addition, seminal work from the Mamula lab elucidated the proteomics and biochemical forms of autoantigens capable of breaking immunologic tolerance to intracellular autoantigens in type I diabetes (T1D) and in systemic lupus erythematosus (SLE). Simply put, Dr. Mamula examines post translational protein modifications that alter cellular biology and immunity. Recent studies have identified early protein modifications of pancreatic beta cells that are sentinels of early disease and dysfunction of glucose metabolism and insulin release (Nature Comm. 2022). Finally, studies from the Mamula laboratory first demonstrated the ability of B lymphocytes to present autoantigens in the triggering of T cell autoimmunity and in the phenomenon of epitope spreading in lupus autoimmunity, work that contributed to the rationale of B cell mediated therapeutics (Rituximab and Belumimab) in SLE. Dr. Mamula has 113 publications and has mentored over 30 pre-and postdoctoral students and investigators, many of whom have acquired faculty positions as independent investigators at major medical schools, universities, and pharmaceutical industries.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Aug 25, 202301:02:05
OsTEAo - An Honest Q&A with Osteosarcoma AYA Patients, Survivors, and Siblings

OsTEAo - An Honest Q&A with Osteosarcoma AYA Patients, Survivors, and Siblings

OsteoWarriors Camille and Mia are joined by members of the MIB Agents Junior Advisory Board to discuss questions submitted by patients, caregivers, clinicians, and researchers. This episode was inspired by the tremendous interest and engagement in the patient panel at the MIB Agents FACTOR 2023 osteosarcoma conference.

Camille, Mia, and our Junior Advisory Board discuss many topics including cancer misconceptions, the cringiest things you can say to someone with cancer, what makes them feel supported and seen in their journey by friends and loved ones, making decisions about surgical options, how they cope with scanxiety and preparing for a procedure, and what gets them through their hardest times.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Aug 17, 202357:17
Treatment of Osteosarcoma Using Smart Targeted Drug Delivery Nanoplatforms

Treatment of Osteosarcoma Using Smart Targeted Drug Delivery Nanoplatforms

Episode sponsored by BTG


Cancer is one of the leading causes of death worldwide. Significant efforts are still necessary to individuate new therapeutic strategies aimed to reduce cancer recurrence and to define new potential adjuvant targets for inhibiting invasion and metastasis, two significant contributors to death among patients. The increasing interest in the employment of nanostructured materials to medicine-related branches is attributable to its unique properties allowing highly efficient drug delivery, molecular sensing applicable in diagnosis, multiplex imaging, or construction of point of care therapeutic devices. This presentation will walk you through our latest developments of functional 3D dual-modality nanostructures for targeted drug delivery of platinum-based complexes.


Václav Ranc received his Ph.D. degree in analytical chemistry in 2009 from the Department of Analytical chemistry, Palacky University in Olomouc, Czech Republic under a supervision of Prof. Karel Lemr. He was then employed at the Department of Analytical chemistry, Palacky University, Olomouc as an assistant professor from 2008 to 2010. In 2011, he joined the team of prof. Rainer at the department of medicine at the University of Fribourg in Switzerland as a research scientist. He worked there from 2011-2012. He has been employed at the Regional center of advanced technologies and materials, Palacký University Olomouc since 2012. He has authored or co-authored 74 scientific publications, H index = 27. He is a co-author of three international patents. His research activities are directed towards development of nano-sensors based on the utilization of Surface enhanced Raman spectroscopy and electrochemistry, and synthesis of functionalized nanomaterials for drug delivery systems.


Aug 11, 202357:20
MIB Agents and SARC: A Case Study in Collaboration

MIB Agents and SARC: A Case Study in Collaboration

Osteosarcoma Webinar Series: Scott Okuno, MD - SARC Medical Officer and Ann Graham, Executive Director of MIB Agents join us on OsteoBites to discuss how SARC (Sarcoma Alliance for Research through Collaboration) work together to drive collaboration in the sarcoma community and support sarcoma research.

--

Dr. Scott Okuno is Professor of Oncology at Mayo Clinic in Rochester, Minnesota. He is a recognized expert in sarcoma and clinical research. Dr. Okuno has been the SARC Medical Officer since 2012. In this role, he provides medical oversight to the day-to-day activities of the SARC clinical trials. Dr. Okuno regularly interacts with the SARC Research Project Management team and the study Principal Investigators to ensure proper study conduct, quality data and overall safety for all SARC clinical trials.  Dr. Okuno was appointed SARC Chief Medical Officer in September 2022, and joined SARC Board of Directors October 2022.


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Aug 04, 202357:36
OSI Funded Work

OSI Funded Work

The Osteosarcoma Institute (OSI) is currently supporting two clinical trials and seven laboratory research projects for osteosarcoma. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chand Khanna, DVM, PhD, Chair of the OSI’s Strategic Advisory Board. Dr. Helman and Dr. Khanna will provide an overview of the OSI’s osteosarcoma research portfolio and explain how the OSI identifies promising osteosarcoma research projects.


Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute.


Chand Khanna, DVM, PhD is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery(501c3), its incubator of scientific innovation. His responsibility at Ethos Discovery is to develop innovations in the form of novel diagnostics and therapeutics for both human and animal patients afflicted with similar complex disease conditions (i.e., osteosarcoma; so called Comparative Oncology). Dr. Khanna is a veterinary oncologist and both osteosarcoma and metastasis biologist, who has worked in this scientific field for over 20 years, most notably as a senior investigator of the Tumor and Metastasis Biology section of the Pediatric Oncology Branch at the National Cancer Institute and founding Director of its Comparative Oncology Program. Dr. Khanna’s research career has focused on improving the understanding of the biology of metastasis in osteosarcoma and the use of a cross species (mouse, dog, human), Comparative and translational approach to develop novel therapeutics for osteosarcoma metastasis. He serves as the Chair of the Osteosarcoma Institute’s Strategic Advisory Board.


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Jul 28, 202301:01:24
OsTEAo - Survivor's Guilt and Grief with grief coach Lori Krause
Jul 20, 202357:18
Pretargeted Approach to Delivery of Radiopharmaceutical Therapy for Bone Cancer - a Click Chemistry Study in Canines with Osteosarcoma

Pretargeted Approach to Delivery of Radiopharmaceutical Therapy for Bone Cancer - a Click Chemistry Study in Canines with Osteosarcoma

Dr. Jeffrey Bryan earned his D.V.M. from the University of California - Davis in 1993. He worked as an Associate Veterinarian from 1993-1995 and served as Medical Director from 1995-2002 of the Irving Street Veterinary Hospital in San Francisco, CA. Bryan then completed a medical oncology residency, a Masters of Biomedical Sciences, and a PhD in Pathobiology at the University of Missouri. He received certification by the American College of Veterinary Internal Medicine in Oncology 2005. He is the Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology, the Director of PET Imaging Center of the University of Missouri, Associate Department Chair for Research, and the Associate Director of Comparative Oncology for Ellis Fischel Cancer Center. Dr. Bryan’s research focuses on comparative examination of cancers in companion animals to better understand cancers in all species. His particular areas of interest are targeted imaging and therapy, epigenetics, and immunotherapy of cancers. He directs the PET Imaging Center, which seeks to develop novel PET imaging agents for cancer diagnosis, localization, and prognostication. He studies DNA methylation of canine non-Hodgkin lymphoma. He studies immunotherapy in companion dogs including investigating fetal microchimerism.


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Jul 14, 202356:32
osTEAo - Coping with Humor: A Review of Cancer Memes
Jun 15, 202347:19
The Importance of Patient-Powered Osteosarcoma Research: Count Me In 

The Importance of Patient-Powered Osteosarcoma Research: Count Me In 

Dr. Katie Janeway, a pediatric hematologist-oncologist of Dana Farber/Boston's Children Hospital, and Benjamin Zola, a Project Manager at Count Me In (CMI), will be joining to share more insight into Count Me In's patient- powered Osteosarcoma research project, and the potential outcomes for discoveries that can have a direct impact on the future osteosarcoma. 

Count Me In (CMI) is a nonprofit research initiative on a mission to make every patient's experience count in the effort to understand and overcome cancer. Founded in 2018 by Emerson Collective,  Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute, Count Me In engages patients and enables them to accelerate cancer research by sharing their samples, clinical information, and voices. From their contributions, Count Me In analyzes and shares de-identified data freely to catalyze discoveries across cancer. Data generated by Count Me In is shared regularly via scientific platforms so that it can be harnessed by researchers everywhere to make impactful discoveries. All individuals living with cancer, including those from marginalized communities who have historically been excluded from research, no matter where they live, can contribute to breakthroughs and increase the pace of biomedical research.

--

Dr. Katie Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children's Hospital, Boston. She was a Chief Resident at Children's Hospital, Boston, and then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute / Children's Hospital, Boston. In 2007, Dr. Janeway joined the staff of Dana-Farber and Children's Hospital, Boston, where she is a pediatric hematologist-oncologist and investigator with a research focus of pediatric sarcomas.


Ben Zola (he/him) is a Project Manager with Count Me In, a nonprofit research initiative that enables patients to accelerate cancer research by sharing their samples, their clinical information, and their voices. Ben has been with the team for over 2 years, and specifically manages Count Me In's projects in Osteosarcoma (osproject.org) and Leiomyosarcoma (lmsproject.org).

Ben has a Bachelors Degree from Rutgers University in Biomedical Engineering, with a minor in Psychology. In his free time, Ben is a fitness instructor and also enjoys being outside and taking pictures of nature.


----


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Jun 09, 202301:02:53
Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars

Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars

Dr. Alice Soragni, PhD, is an Assistant Professor in the David Geffen School of Medicine at UCLA, a member of the Jonsson Comprehensive Cancer Center and of the UCLA Molecular Biology Institute. She has a Master of Science cum Laude from the University of Bologna, Italy and a PhD from the ETH of Zuerich, Switzerland. Her laboratory in the Department of Orthopaedic Surgery at UCLA couples basic research into mechanisms of disease to the development of novel therapeutic strategies. The lab focuses on developing tumor organoid models to investigate the biology of rare tumors and to perform screenings for precision medicine applications.

---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Jun 02, 202301:01:07
Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases

Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases

Dr. Christian Capitini is an associate professor and the Jean R. Finley Professor of Pediatric Hematology and Oncology. He serves as co-leader of the Developmental Therapeutics Program at the University of Wisconsin Carbone Cancer Center and director of clinical innovation at the Forward BIO Institute. He has received many awards for his clinical and research contributions, including the Department of Pediatrics Gerard B. Odell Research Award, the Outstanding New Member Science Award from the Society for Pediatric Research (SPR), and the Janet Rowley Award from the Jonas Center Cellular Therapy Symposium at the University of Chicago. Nationally, Dr. Capitini is an active member of the Society for Immunotherapy of Cancer (SITC) and serves as at-large director. Additionally, he serves on the executive board for the Pediatric Real World chimeric antigen receptor (CAR) T Consortium.

Dr. Capitini leads an NIH-supported laboratory focusing on development of cell-based immunotherapies, including natural killer (NK) cells and CAR T cells, for the treatment of pediatric solid tumors. The Capitini Lab also develops alternatively activated macrophages for complications of bone marrow transplant, including graft-versus-host-disease (GVHD) and acute radiation syndrome. Dr. Capitini was one of the site principal investigators (PI) for the first multicenter CD19 CAR T cell trial, which led to the FDA approval of tisagenlecleucel-T (Kymriah) for relapsed/refractory B cell leukemia. Currently, he is site PI for a Kymriah trial related to the upfront treatment of high-risk B cell leukemia and for a multicenter GD2 CAR T cell trial for neuroblastoma and osteosarcoma through the Pediatric NCI-Cancer Immunotherapy Trials Network (CITN). He is also a sponsor and PI for a University of Wisconsin clinical trial expanding gamma delta T cells in vivo using zoledronate after alpha beta T cell depleted stem cell transplant.


---


What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

May 26, 202356:34
osTEAo- Returning to Yourself: Confidence and Identity as an AYA Cancer Patient
May 18, 202347:25
OSI Connect: Osteosarcoma Answers and Assistance

OSI Connect: Osteosarcoma Answers and Assistance

OSI Connect is the Osteosarcoma Institute’s free, easy-to-use resource for patients who have been diagnosed with osteosarcoma or suffered a relapse after initial treatment. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chelsey Blanks, OSI Connect Administrator. You will learn how OSI Connect works and examples of how the program has helped more than 70 patients since its launch in 2019.


Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute.


As the Osteosarcoma Institute Operations Manager, Chelsey Blanks schedules meetings for the board, oversees various operational aspects of the organization (including HR, IT, and office management), facilitates the grant cycle, and manages OSI Connect (formerly OSI Hotline) that offers free expert advice for osteosarcoma patients and families no matter where they are in their journey. Although Chelsey is Texan through and through, she spent six years living in Southern California and was thrilled to return to the homeland with her husband, Jordan, at the end of 2019. Chelsey obtained her undergraduate degree from the University of North Texas, where she studied Sociology, Philosophy, and Dance. Previously, she had an insurance and financial services career and was an Executive Assistant for her church in Orange County, California.


---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

May 12, 202358:30
Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

*Please note : The safety and efficacy of GD2-SADA:177Lu-DOTA Drug Complex have not been established and have not been approved by health authorities in the US or globally.


Janet Yoon, M.D., specializes in pediatric hematology/oncology because it allows her to build long-term relationships with her young patients and their caregivers. Inspired by their resilience and strength, she stays at the leading edge of her field so that she can introduce families to the latest therapies, specifically those that minimize harmful and long-lasting side effects.

 

Dr. Yoon received her medical degree from the Medical College of Ohio and then served as a pediatric resident at the Medical University of South Carolina. She moved to California to pursue a pediatric hematology/oncology fellowship at Children’s Hospital Los Angeles. Prior to City of Hope, Dr. Yoon was at University of California Davis Medical Center then spent over a decade at University of California San Diego/Rady Children’s Hospital San Diego where she was a clinical professor and director of the pediatric solid tumor program. At Rady, she was honored twice with the Dr. William D. Roberts Pediatric Hematology Oncology Faculty Teaching Award.

 

Dr. Yoon’s research is dedicated to understanding and treating sarcomas, particularly in the adolescent and young adult population. She is actively involved in clinical trials.


---

What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

May 09, 202329:18
SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53

SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53

Apr 28, 202359:17
osTEAo - Navigating Scanxiety
Apr 20, 202348:59
Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?

Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?

Cristina Canal Barnils (Barcelona 1977) is Associate professor at the Department of Materials Science and Engineering, at the Technical University of Catalonia (UPC), head of the PlasmaMedLab: Plasmas for BioMedical Applications Laboratory and of the Medical Technologies: Biomaterials & Tissue Engineering research group at the IRSJD.


Before joining UPC, she did different research stages at pre and postdoctoral level in different national and international research centres. She has participated and lead a number of research projects, as well as technology transfer projects in the areas of Textile materials, Biomaterials and Cold Plasmas. Her research has led to above 60 publications, and several invited conferences. Her research has been recognized with different awards, including the L’Oreal-Unesco fellowship “For Young Women in Science” (2012), the “2018 Early Career Award in Plasma Medicine“ and the  ICREA Acadèmia 2020.


Her interests are focused in cold plasmas for biomedical applications, particularly: i. Surface modification of biomaterials to control parameters such as adhesion or biological behaviour; ii. Control of drug release from biomaterials; and iii. Therapeutical appications of cold plasmas, for instance, in bone cancers.


She is currently ERC APACHE project Starting Grant leader in a project in the field of atmospheric pressure plasma therapy, her main axis of research being currently focused in the atmospheric pressure plasma therapy of bone cancer treatment in combination with biomaterials.


---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨ 


Apr 14, 202357:49
UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression

UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression

Dr. Claudia Benavente studied Molecular Biotechnology Engineering at Universidad de Chile where her interest in pursuing cancer research first started. To further her studies, she came to the US to pursue a doctoral degree in Cancer Biology at The University of Arizona as a Fulbright scholar. She then moved on as a postdoctoral fellow to St. Jude Children’s Research Hospital in Memphis, TN where she became familiar with childhood solid tumors. Professor Benavente is currently an Associate Professor at the Departments of Pharmaceutical Sciences and Developmental and Cell Biology and a member of the Chao Family Comprehensive Cancer Center at the University of California, Irvine. Dr. Benavente’s research focuses on understanding how pediatric tumors form to design new ways to treat them. Her research aims to understand how genes are normally controlled in developing tissues and how epigenetic processes are perturbed to facilitate cancers to arise. This information guides her in the development of new therapies.


---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨ 

Mar 31, 202301:00:16
Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) for Sarcoma
Mar 24, 202358:16
osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives

osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives

OsteoWarriors Camille and Mia are joined by OsteoWarriors Daniel and Kara in this episode on navigating life and campus with limb salvage surgery and amputation, which are the primary treatment options to remove an osteosarcoma tumor. Listen in as they discuss why they chose limb salvage surgery or amputation and how they manage getting around school, and share challenges and horror stories they've experienced which are sure to make you both grimace and laugh.

---

Save the Date and mark your calendars for FACTOR 2023 - June 22-24 in Atlanta GA. Registration is now live! Go to MIBAgents.org to register.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org
 Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Mar 16, 202354:48
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

Dr. Kelly M. Bailey MD, PhD, is a pediatric oncologist certified by the American Board of Pediatrics. She is assistant professor of pediatrics at the University of Pittsburgh School of Medicine. Dr. Bailey received her medical degree and PhD from West Virginia University, Morgantown, W.Va., and completed her residency in pediatrics and fellowship in pediatric hematology/oncology at the University of Michigan School of Medicine, Ann Arbor, Mich. Dr. Bailey’s clinical and research interests focus on pediatric sarcomas, specifically Ewing sarcoma. Nationally, Dr. Bailey is active in the Children’s Oncology Group Bone Tumor Committee and the New Agents for Ewing Sarcoma Task Force.

Dr. Bailey’s studies the rare primary pediatric bone tumor Ewing sarcoma. Her research focuses on understanding the intersection of DNA damage and immunoregulation of this tumor.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Mar 10, 202301:00:33
SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care

SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care

Surgery along with chemotherapy is the mainstay of treatment for patients with osteosarcoma. In order to achieve a cure, during surgery healthy tissue surrounding the tumour is also removed. Whilst this reduces the chances of the cancer returning, it can also result in added pain and disability for patients, impacting their quality of life in the longer-term. Advancements in surgical technology and technique offer the hope of improved outcomes for patients.

Recent developments have led to the introduction of fluorescence guided surgery (FGS), a technique which harnesses the emission of light to identify a tumour’s precise location and boundaries during surgical removal. This improves a surgeon’s ability to successfully remove the entire tumour, which can be identified as a ‘glowing’ area of tissue, decreasing the likelihood of any cancer cells remaining, while limiting the removal of too much healthy tissue.

This upcoming clinical trial, led by Kenneth Rankin, a leading Consultant Orthopaedic Surgeon and bone sarcoma researcher, is looking to assess the effectiveness of a particular fluorescent dye, indocyanine green or ‘ICG’, which can be given to patients safely before surgery and leads to the sarcoma tumour fluorescing green. The SarcoSIGHT trial will recruit 500 patients undergoing surgery for bone and soft tissue sarcoma, aiming to test whether the use of ICG in FGS can help to accurately identify the tumour, aid in complete removal and reduce the amount of healthy tissue removed.

This presentation will include the findings to date from fluorescence guided surgery in osteosarcoma patients with some initial results indicating that the amount of fluorescence may predict response to chemotherapy and that the osteosarcoma tissue can be studied in detail post-operatively with the latest fluorescence microscopy techniques.

---

Mr Kenneth Rankin is a Consultant Orthopaedic Surgeon at Newcastle’s Freeman Hospital where his specialist interests are in orthopaedic oncology including fluorescence guided surgery for sarcoma resection, and hip and knee replacement for arthritis.

Mr Rankin graduated in 1999 from the University of Dundee. His basic surgical training was in Newcastle followed by an MD investigating the cellular biology of bone metastases. Mr Rankin completed his higher specialist training in Perth and Dundee followed by a return to the North East as NIHR Academic Clinical Lecturer.

His current post as Consultant Orthopaedic Surgeon and Honorary Senior Lecturer is comprised mainly of orthopaedic oncology including the surgical management of bone and soft tissue sarcomas and metastatic bone disease. He also carries out hip and knee replacements for arthritis. As a Clinical Scientist Mr Rankin has developed an international reputation for translational research for the detection of circulating tumour cells in sarcoma patients and carried out the world’s first case series of fluorescence guided surgery in sarcoma. Working in close collaboration with scientists at Newcastle University, he leads on basic and translational sarcoma research at the Newcastle Centre for Cancer.


Mar 03, 202358:56
Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections

Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections

Jayanthi Parthasarathy BDS, MS, PhD, manages the 3D Printing Lab at Nationwide Children’s Hospital, which provides comprehensive patient-specific treatment planning and device development services from a pediatric perspective. She will discuss virtual surgical planning and 3D printing in pediatric musculoskeletal oncological resections.


A trained dental surgeon with more than 3 decades of practice, Dr. Parthasarathy is a pioneer in additive manufacturing for clinical needs, specializing in the development of patient-specific medical devices using advanced design and manufacturing technologies,  having used the technology for more than 2 decades. With a masters in manufacturing and a doctorate in industrial engineering has researched on design and manufacturing of patient-specific devices using 3D printing and material composition for medical 3D printing. Dr. Parthsarathy worked in the medical device industry specializing in bringing to market patient-specific implantable and non-implantable adult and pediatric devices from ideation to production. She is currently managing the point of care 3D printing program in the department of radiology at Nationwide Children’s Hospital in Columbus, Ohio, U.S.A - one of the largest pediatric referral hospitals in the country. She works with all specialties across the board, cardio-thoracic, plastic and reconstructive, orthopedic, neuro, oncologic and pediatric surgeons for virtual surgical planning, design, and manufacturing of patient-specific devices for surgical guidance and simulation.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Feb 17, 202301:05:53
Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response

Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response

Jan 27, 202354:03
Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Marie Nelson, M.D., is originally from Michigan, attended college at the University of Notre Dame and earned her medical degree from Loyola University Chicago Stritch School of Medicine. She finished her residency in Pediatrics at Ann & Robert H. Lurie Children’s Hospital of Chicago prior to completing a fellowship in Pediatric Hematology, Oncology, and Bone Marrow Transplantation at Children’s National Hospital in Washington, D.C. Dr. Nelson is a member of the solid tumor faculty and Assistant Professor of Pediatrics at Children’s National Hospital where she also leads the Adolescent and Young Adult Oncology Program. Her research focuses on combining local therapies and immunotherapy in order to improve the outcomes and reduce the side effects of treatment for pediatric patients with solid tumors.

She is the principal investigator of a phase II trial combining cryoablation and immune checkpoint inhibitors in pediatric solid tumors.

---

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Jan 13, 202351:37
Cell Based Therapies for Osteosarcoma
Dec 09, 202201:05:17
osTEAo Q&A with Dr. Kurt Weiss - What questions do you have about Osteosarcoma but are afraid to ask?
Nov 17, 202201:02:39
Interventional Radiology/HIFU Perspectives for Osteosarcoma

Interventional Radiology/HIFU Perspectives for Osteosarcoma

Karun V. Sharma, M.D., Ph.D., is the Director of Interventional Radiology at Children's National Hospital, and an Associate Professor of Pediatrics and Radiology at the George Washington University School of Medicine and Health Sciences. His clinical practice and translational research focuses on minimally invasive  image-guided therapies for musculoskeletal and oncology conditions. Dr. Sharma leads the Image-Guided Non-Invasive Therapeutic Energy (IGNITE) program, a collaboration of the Sheikh Zayed Institute and the departments of Radiology, Oncology, Surgery, and Anesthesiology at Children’s National Hospital. The IGNITE program aims to improve the quality of life and outcomes for pediatric patients through the development and clinical translation of novel minimally invasive and noninvasive surgery technologies and combination therapy approaches, with the ultimate goal of making pediatric surgery more precise, less invasive and pain-free. In the recent years, Dr. Sharma and the IGNITE team have developed Magnetic Resonance Imaging –guided High Intensity Focused Ultrasound (MR-HIFU) applications for pediatric patients and lead clinical trials for osteoid osteoma and other tumors.

AeRang Kim, M.D., Ph.D., is a member of the solid tumor faculty at Children’s National Hospital and an Associate Professor of Pediatrics. Dr. Kim's specializes in sarcomas and developmental therapeutics. Her research focuses on development of novel therapeutics for pediatric cancer including pre-clinical testing of novel agents, pharmacokinetic analysis, developing innovative methods for toxicity monitoring and clinical trial design. She serves as the principal investigator of multiple early phase trials in pediatric oncology, sarcomas and NF1 associated tumors.

--- 

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Nov 11, 202201:02:31